Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.83 |
| ▸ | F9 | P00740 | 4/20 | 0.83 |
| ▸ | F7 | P08709 | 3/20 | 0.83 |
| ▸ | F11 | P03951 | 3/20 | 0.83 |
| ▸ | PLAU | P00749 | 10/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.56 |
| ▸ | F2 | P00734 | 9/20 | 0.54 |
| ▸ | PLG | P00747 | 9/20 | 0.54 |
| ▸ | PLAT | P00750 | 8/20 | 0.54 |
| ▸ | HPN | P05981 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7973776 | 0.91 | F10 (1.00) | F10F9F7F11PLAU | |
| SCHEMBL7959410 | 0.84 | F10 (0.79) | F10F9F7F11PLAU | |
| SCHEMBL7977546 | 0.83 | F10 (0.68) | F10F9F7F11PLAU | |
| SCHEMBL10140012 | 0.81 | F10 (0.56) | F10F9F7F11PLAU | |
| SCHEMBL7972717 | 0.81 | F9 (0.77) | F10F9F7F11 | |
| SCHEMBL7973134 | 0.80 | F10 (0.64) | F10F9F7F11PLAU | |
| SCHEMBL14519373 | 0.80 | PLAU (0.73) | F10F7PLAUPRSS1F2 | |
| SCHEMBL7974859 | 0.79 | F9 (0.68) | F10F9F7F11PLAU | |
| SCHEMBL10139860 | 0.78 | F9 (0.69) | F10F9F7F11 | |
| SCHEMBL7982582 | 0.78 | F10 (0.76) | F10F9F7F11PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009143039-A2 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |